Sanofi

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales.[3] Originally, the company was formed in 1973 and the current incarnation was formed as Sanofi-Aventis in 2004, by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.[4]

Sanofi S.A.
Formerly
  • Sanofi-Synthélabo
    (1999–2004)
  • Sanofi-Aventis
    (2004–2011)
Société Anonyme
Traded asEuronext Paris: SAN
NASDAQ: SNY
CAC 40 Component
ISINFR0000120578 
IndustryPharmaceuticals
PredecessorMarion Merrell Dow 
Founded1973 (1973)
FounderElf Aquitaine 
Headquarters54 Rue La Boétie
Paris, France 75008
Area served
Worldwide
Key people
  • Serge Weinberg (chairman)
  • Paul Hudson (CEO)​ (Sep 2019–present)
  • Jean-François Dehecq​ (founder)
ProductsPrescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...)
Revenue €36.126 billion (2019)
€4.676 billion[1][2] (2018)
€4.423 billion[1][2] (2018)
Total assets €111.408 billion[1][2] (2018)
Total equity €59.035 billion[1][2] (2018)
Number of employees
 104,226[2] (2018)
Subsidiaries
Websitewww.sanofi.com

Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).[5]

History

Sanofi-Synthélabo

Sanofi was founded in 1973[6] as a subsidiary of Elf Aquitaine (a French oil company subsequently acquired by Total), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company formed in 1947, by Sociéte Belge de l'Azote et des Produits Chimiques du Marly;[7] Labaz developed benziodarone in 1957.[8]:146 In 1993, Sanofi made a move into the Eastern Europe market by acquiring a controlling interest in Chinoin, a Hungarian drug company that had about US$104 million in sales in 1992.[9][10] In that same year, Sanofi's made its first significant venture into the U.S., and strengthened its presence in Eastern Europe, by first partnering with Sterling Winthrop and then acquiring the prescription pharmaceuticals business in 1994.[9][11] Sanofi was incorporated under the laws of France in 1994, as a société anonyme, a form of limited liability company.[12]:18

Synthélabo was founded in 1970, through the merger of two French pharmaceutical laboratories, Laboratoires Dausse (founded in 1834) and Laboratoires Robert & Carrière (founded in 1899). In 1973, the French cosmetics group L'Oréal acquired the majority of its share capital.[12]:19 In 1991, Synthelabo acquired Laboratories Delalande[13] and Laboratoires Delagrange, and through this deal picked up the product metoclopramide.[14][15]

Logo for Sanofi-Synthélabo (1999—2004)

Sanofi-Synthélabo was formed in 1999, when Sanofi merged with Synthélabo; at the time of the merger Sanofi was the second largest pharmaceutical group in France in terms of sales and Synthélabo was the third largest. The merged company was based in Paris, France.[12]:18–19[16]

The merged companies focused on pharmaceuticals, divesting several businesses soon after the merger, including beauty, diagnostics, animal health and nutrition, custom chemicals, and two medical equipment businesses.[12]:19

Aventis

Aventis was formed in 1999, when French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Cassella, Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.[17]:13[18]:9–11[19]:40–41

At the time of the merger, Rhône-Poulenc's business included the pharmaceutical businesses Rorer, Centeon (blood products), and Pasteur Merieux (vaccines), the plant and animal health businesses Rhône-Poulenc Agro, Rhône-Poulenc Animal Nutrition, and Merial, and a 67 percent share in Rhodia, a speciality chemicals company.[18]:10 Hoechst, one of the companies resulting from the post-WWII split of IG Farben, had seven primary businesses: Hoechst Marion Roussel (pharmaceuticals), AgrEvo (a joint venture with Schering in crop protection agents and pest control products), HR Vet (veterinary products), Dade Behring (diagnostics), Centeon, Celanese (chemicals), and Messer (chemicals).[18]:9 Merieux has been in the business of selling blood products, and In the 1980s during the AIDS epidemic, Merieux and other companies were involved in scandals related to HIV-contaminated haemophilia blood products that were sold to developing nations.[20]

In 2000, Aventis and Millennium Pharmaceuticals, a US biotechnology company formed to discover new drugs based on the then-new science of genomics, announced that Aventis would make a $250M investment in Millennium and would pay $200M to Millennium in research fees over five years, one of the largest such deals between a big pharmaceutical company and a biotech company at the time.[21]

In late 2000, in the midst of the recall of Starlink, its genetically modified maize product, Aventis announced that it had determined to sell off Aventis Cropscience, the seed and pesticide business unit it had created from the agriculture businesses of its predecessors.[22] In October 2001, Bayer and Aventis announced that Bayer would acquire the unit for about $6.6 billion, with the unit becoming Bayer CropScience and making Bayer the world's second-largest agrochemical company behind Syngenta.[23]

In 2003, Aventis entered into a collaboration with Regeneron Pharmaceuticals, a New York biotechnology company, to develop Regeneron's VEGF-inhibiting drug, aflibercept, in the field of cancer, which was then in Phase I clinical trials. Aventis invested $45 million in Regeneron and made an upfront payment of $80 million in cash.[24] Regeneron partnered the drug with Bayer Healthcare in the field of proliferative eye diseases, and under the name Eylea it was approved by the U.S. Food and Drug Administration (FDA) in 2011;[25] after several setbacks in clinical trials,[26] Regeneron and Sanofi got the drug approved in metastatic colorectal cancer in combination with other agents, under the brand name Zaltrap in 2012.[27]

Sanofi-Aventis merger

Sanofi-Aventis was formed in 2004, when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 billion for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value, and the board of Aventis went so far as to enact poison pill provisions and to invite Novartis to enter merger negotiations.[28] The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. The French government played a strong role, desiring what it called a "local solution", by putting heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis and for Aventis to accept the offer[29] and by rejecting Aventis' poison pill proposal.[30] One of the largest risks in the deal for both sides, was the fate of the patents protecting Clopidogrel (Plavix) which was one of the top-selling drugs in the world at the time and the major source of Sanofi's revenue.[31]

Post-merger activities

In 2006, Iraqis infected with HIV sued Sanofi and Baxter due to HIV-contaminated haemophilia blood products sold by Merieux in the 1980s.[32] In 2006, the US patents on clopidogrel (Plavix) were challenged when a Canadian generics company, Apotex, filed an Abbreviated New Drug Application under the Hatch-Waxman Act, received FDA approval, and started marketing a generic clopidogrel. While Sanofi-Aventis and its partner on the drug, Bristol Myers Squibb (BMS), were able to get an injunction to stop Apotex from selling the drug,[33] the case became complicated when settlement negotiations fell apart twice – the second time due to an oral agreement made by BMS CEO Peter Dolan that BMS failed to disclose to the Federal Trade Commission during the review of the settlement agreement to ensure that it did not violate antitrust law. When Apotex disclosed the oral agreement to the FTC, the FTC launched an investigation that led to Dolan being fired by BMS.[34] Apotex finally lost on the patent litigation issues after its third appeal was decided in favor of BMS/Sanofi in November 2011; Apotex had to pay ~$442 million in damages and ~$108 million in interest for infringing the patent,[35] which it paid in full by February 2012.[36] Apotex also sued BMS and Sanofi for $3.4 billion for allegedly breaching the settlement agreement, and Apotex lost a jury trial in March 2013.[37]

In 2007, Sanofi-Aventis expanded on Aventis' prior relationship with Regeneron Pharmaceuticals; in the new deal Sanofi-Aventis agreed to pay Regeneron $100 million each year for five years, under which Regeneron would use its monoclonal antibody discovery platform to create new biopharmaceuticals, which Sanofi-Aventis gained the exclusive right to co-develop.[38] In 2009, the companies expanded the deal to $160 million per year and extended it through 2017.[38][39] As of 2009, the collaboration had four antibodies in clinical development and had filed an IND for a fifth. Two were against undisclosed targets, one targeted the interleukin-6 receptor as a treatment for rheumatoid arthritis, another targeted nerve growth factor for the treatment of pain, and another targeted delta-like ligand 4 as a treatment of cancer.[39]

Between 2008, when Chris Viebacher was hired as CEO, and 2010, the company spent more than $17 billion in mergers and acquisitions to strengthen its consumer healthcare and generics platforms, especially in emerging markets, in the face of looming patent cliffs and the growth of the consumer healthcare segment.[40][41][42] In September, Zentiva was acquired for €1.8 billion, expanding the group's eastern European markets presence.[43]

In 2009, Medley Farma, the third largest pharmaceutical company in Brazil and a leading generics company in that country, was acquired for about $635 million.[44] Sanofi outbid Teva Pharmaceuticals.[45] The deal was approved by Brazil's antitrust authorities in May 2010.[44] Later that year, Indian vaccine manufacturer Shantha Biotechnics was acquired for $784 million.[46] In October Sanofi-Aventis announced that it would lay off about 1,700 US employees (about 25% of its US workforce) due to restructuring triggered by growing generic competition and other factors, and that the company would focus its US operations on diabetes, atrial fibrillation and oncology.[47]

In 2010, U.S. consumer healthcare company Chattem, Inc. was acquired for around $1.9 billion.[42] In the same year, Nepentes Pharma was acquired for $130 million and BMP Sunstone Corporation for $520.6 million.[48]

Name change, acquisitions and investments

The company dropped the -Aventis suffix of its name on 6 May 2011, after receiving approval at its annual general meeting. The reason given by the company for the change was to make its name easier to pronounce in countries such as China.[49]

In 2011, Genzyme Corporation was acquired for around $20.1 billion. This biotechnology company headquartered in Cambridge, Massachusetts specializes in the treatment of orphan diseases, renal diseases, endocrinology, oncology and biosurgery.[50]

In January 2012, Sanofi co-invested in the $125 million Series A financing of Warp Drive Bio. Sanofi sought support for its internal cancer research program and also took on an obligation to acquire Warp Drive if certain milestones were met.[51]

In January 2014, Genzyme and Alnylam Pharmaceuticals, a US biotechnology company developing RNAi therapeutics, announced that Genyzme would invest $700 million in Alnylam. Under the deal, Genzyme obtained further rights to patisiran, an RNAi treatment for transthyretin-mediated amyloidosis – a condition that can result in familial amyloidotic polyneuropathy and familial amyloidotic cardiomyopathy -[52] and obtained rights to other compounds in Alnylam's pipeline.[53]

In March 2014, Sanofi joined the bidding for Merck & Co.'s over-the-counter health-products unit, the maker of Coppertone sunblock and Claritin allergy medicine; bids were expected to range between $10 billion and $12 billion.[54]

In October 2014, Sanofi's directors fired US-resident chief executive Chris Viehbacher, blaming his alleged lack of communication with the board and poor execution of his strategy.[55] Board chairperson Serge Weinberg took over as interim CEO until 2 April 2015 when Bayer Healthcare board chairperson Olivier Brandicourt (appointed by Sanofi on 19 February 2015[56]) took over. Before Brandicourt even started his new job, French government ministers Stéphane Le Foll and Ségolène Royal attacked the $4.5 million golden handshake he was getting from Sanofi – and his pay of about $4.7 million a year.[57] Further, in 2014, the business took a 66% stake in Globalpharma, Dubai-based generics manufacturer.[58]

In July 2015, Genzyme announced it would acquire the rare cancer drug Caprelsa (vandetanib) from AstraZeneca for up to $300 million.[59] In the same month In July 2015, the company announced a new global collaboration with Regeneron Pharmaceuticals to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron,[60] with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810.[61]

In June 2016, the company announced it had struck an asset-swap deal with Boehringer Ingelheim. Sanofi would sell its Merial animal health division (valuing it at €11.4 billion), whilst acquiring Boehringer's consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash. The deal means Sanofi is now one of the global consumer healthcare leaders by market share.[62]

In July 2017, the company announced its intention to acquire Protein Sciences, a privately held, Connecticut-based vaccines biotechnology company, for $650 million and with up to $100 million in milestone achievements.[63]

In January 2018, Sanofi announced that it would acquire Bioverativ for $11.6 billion[64] and days later announced it would acquire Ablynx for €3.9 billion ($4.8 billion).[65]

In December 2019, the company announced it would acquire Synthorx for $2.5 billion ($68 per share), adding the lead product candidate THOR-707, a form of interleukin-2 (IL-2) being developed for use against multiple solid tumours.[66][67]

In May 2020 Regeneron announced it would repurchase around $5 billion of its shares, held directly by Sanofi. Prior to the transaction Sanofi held 23.2 million Regeneron shares.[68] In June, the company announced it had agreed a potential $2 billion deal with Translate Bio, expanding an already existing collaboration for COVID-19 treatments.[69] The company agreed to produce 60 million doses of a coronavirus vaccine for the United Kingdom government in July 2020. It uses recombinant protein-based technology for Sanofi's flu vaccine along with GSK's pandemic technology and was seeking regulatory approval by the first half of 2021.[70] Sanofi also agreed to a $2.1 billion deal with the United States for 100 million doses.[71]

Company financials
Historical financial data (in billions of euro)[72][73][74][75][76][2][77]
Year2001200220032004200520062007200820092010201120122013201420152016 2017 2018 2019
Revenue6.0697.4488.04814.8727.3128.3728.0527.5729.3130.3833.3934.9530.9731.6934.5433.82 35.07 34.46 36.13
Net Income1.0981.6401.865-3.6652.2024.0065.2633.8515.2655.4675.6464.8883.7164.3904.2874.800 8.42 4.31 2.81
Assets18.2317.3617.4282.8586.2477.7671.9171.9980.2585.26100.7100.496.0697.39102.3104.7 99.81 111.41 112.74
Equity12.7512.6012.7441.6346.4045.6044.5444.8748.3253.1056.1957.3556.956.1258.0557.72 58.07 58.88 58.93

Note. In 2001—2004 — Sanofi-Synthélabo, in 2004—2011 — Sanofi-Aventis.

Acquisition history
Sanofi Acquisitions
  • Sanofi
    • Sanofi–Aventis
      • Aventis (Merged 2004)
      • Sanofi-Synthélabo (Merged 2004)
        • Sanofi (Est 1973 as subsidiary of Elf Aquitaine)
          • Midy
          • Sterling Winthrop (Acq 1994)
        • Synthélabo
          • Laboratoires Dausse (Founded 1834, merged 1970)
          • Robert & Carrière (Founded 1899, merged 1970)
      • Zentiva (Acq 2008)
        • Leciva Slovakofarma (Acq 2003)
        • Sicomed SA Bucharest (Acq 2005)
      • Medley Farma (Acq 2009)
      • Shantha Biotechnics (Acq 2009)
      • Chattem (Acq 2010)
      • Nepentes Pharma (Acq 2010)
      • BMP Sunstone Corporation (Acq 2010)
    • Genzyme Corporation (Acq 2011)
      • Whatman Biochemicals Ltd (Acq 1981)
      • Koch-Light Laboratories (Acq 1982)
      • Integrated Genetics (Acq 1989, spun off 1991)
      • Genecore International (Diagnostic enzyme div, acq 1991)
      • Medix Biotech, Inc. (Acq 1992)
      • Enzymatix Ltd (Acq 1992)
      • Vivigen (Acq 1992)
      • Virotech (Acq 1993)
      • Omni Res srl (Acq 1993)
      • Sygena Ltd (Acq 1994)
      • BioSurface Technology Inc. (Acq 1994)
      • TSI Inc. (Acq 1994)
      • PharmaGenics, Inc. (Acq 1997)
      • Biomatrix (Acq 2000)
      • SangStat Medical Corp. (Acq 2003)
      • Ilex Oncology Inc. (Acq 2004)
      • Bone Care International Inc. (Acq 2005)
      • AnorMED Inc. (Acq 2006)
      • Bioenvision (Acq 2007)
    • Protein Sciences (Acq 2017)
    • Bioverativ (Acq 2018)
      • True North Therapeutics (Acq 2017)
    • Ablynx (Acq 2018)
    • Synthorx (Acq 2019)

Products

The following products are found on the Sanofi website. Generic drug names are given in parentheses following the brand name.

– Autoimmune

Product recall and effects: The Epinephrine auto-injection devices made by Sanofi SA currently on the market in the U.S. and Canada were voluntarily recalled on 28 October 2015.[81][82] The reason stated by Sanofi was that the products have been found to potentially have inaccurate dosage delivery, which may include failure to deliver drug.[83][84]

Sanofi US also added the following warning: If a patient experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death because anaphylaxis is a potentially life‑threatening condition.[83]

In its news release on 28 October 2015, Sanofi Canada stated that it was "actively working with suppliers of alternative epinephrine auto-injectors to have a full stock available in Canada as soon as possible. Canadian customers were asked to immediately return the Allerject product to their local pharmacy to obtain an alternate epinephrine auto-injector."[85]

The U.S. Food and Drug Administration (FDA) also filed a news release[84] confirming that the recall involves all Auvi-Q currently on the market in the U.S. The FDA release went on to provide information for consumers re: exchanging the device for another brand of product, also provided on the Auvi-Q web site. Sanofi US will provide reimbursement for out of pocket costs incurred for the purchase of new, alternate epinephrine auto-injectors with proof of purchase.

The alternate products expected to most commonly replace the recalled Sanofi devices are the EpiPens made by Mylan in the US and by Pfizer—under license from Mylan—in Canada.[86] Mylan already had an 85% market share of the auto-injectors in the US[87] in the first half of 2015. Maylan was expected to benefit from the recall by its competitor Sanofi, according to a report published in the Fierce Pharma newsletter of 2 November 2015: "....it is very hard to see Auvi-Q returning to the market, as it will need to be redesigned and face uphill battle to recapture patient trust after the recall," Bernstein analyst Ronny Gal wrote in a note to clients.[88] Gal also believes that the company will eventually have 95% of the Epinephrine auto-injector market, according to another Fierce Pharma report on 3 November 2015.[89]

– Cardiovascular

– Dermatology

– Diabetes

  • Adlyxin (Lixisenatide), for type 2 diabetes mellitus.
  • Admelog (insulin lispro), for type 1 and type 2 diabetes mellitus.
  • Afrezza (Inhalable insulin), for type 1 and type 2 diabetes mellitus.
  • Amaryl (Glimepiride), for type 2 diabetes mellitus.
  • Apidra (insulin glulisine), for type 1 and type 2 diabetes mellitus.
  • Diabeta (Glyburide), for type 2 diabetes mellitus.
  • Glucophage (Metformin), for type 2 diabetes mellitus, marketed by EMD Serono.
  • Insuman (Human insulin), for type 1 and type 2 diabetes mellitus.
  • Lantus (insulin glargine), for type 1 and type 2 diabetes mellitus.
  • Soliqua (insulin glargine/lixisenatide), for type 2 diabetes mellitus.
  • Toujeo (insulin glargine), for type 1 and type 2 diabetes mellitus.

– Endocrinology

– Gastroenterology

– Hematology

– Infectious diseases

– Metabolic

– Neurology

– Oncology

– Other

– Over the counter

– Pain

– Respiratory and inflammatory diseases

– Rheumatology

– Urology

  • Ditropan XL (Oxybutynin chloride), for bladder relief, marketed by Janssen.
  • Eligard (Leuprorelin), for prostate cancer, marketed by Astellas.
  • Flomax (Tamsulosin), for bladder relief, marketed by Astellas.

The company also produces a broad range of over-the-counter products, among them Allegra, IcyHot for muscle pain, Gold Bond for skin irritation, and Selsun Blue dandruff shampoo. These brands were acquired in 2010, when Sanofi-Aventis purchased Chattem.

Pipeline

As of 2013, Sanofi was in a race with Amgen and Pfizer to win approval for a drug that inhibits PCSK9, a protein that slows the clearance of low-density lipoprotein (LDL) cholesterol – the form of cholesterol that leads to heart attacks.[95] Sanofi's drug was discovered by Regeneron Pharmaceuticals and is called alirocumab.[96] An FDA warning in March 2014, about possible cognitive adverse effects of PCSK9 inhibition threw the competition into disarray, as the FDA asked companies to include neurocognitive testing into their Phase III clinical trials.[97]

In 2013, Sanofi announced that another candidate from its collaboration with Regeneron, the monoclonal antibody against the interleukin 6 receptor, sarilumab, had better efficacy than placebo in its first Phase III trial for rheumatoid arthritis.[98]

Management

Stockholders

As of 31 December 2013:[101]:185

  • Breakdown of share ownership: 8.93% by L'Oréal, 0.27% treasury shares and 1.31% employees. The remaining 89.49% were publicly traded.[upper-alpha 1]

Head office
Head office 54 rue de la Boétie, Paris 8th arrondissement
Former head office 174 avenue de France, Paris 13th arrondissement

In January 2012, Sanofi moved its head office location to 54, Rue La Boétie in the 8th arrondissement of Paris. This former mansion designed by architect René-Patouillard had previously been the head office of Alcatel-Lucent.

Sanofi's previous head office was located in the 13th arrondissement of Paris, 174 Avenue de France. The architecture of the head office is of the predominant style of the area surrounding the François Mitterrand Library. After Sanofi and Aventis merged, the employees at the former Aventis head office in Schiltigheim, Alsace, moved to Paris.[103]

Collaborative research

In addition to internal research and development activities Sanofi is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox project[104][105] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[106]

In June 2010, Sanofi and the Charite University of Berlin signed a cooperation agreement for the research and development of medicines and therapies.[107]

On 25 October 2012, Sanofi said its earnings for the third quarter slumped as generic competitors ate into profits of its Eloxatin cancer treatment.[108]

Sanofi Pasteur
Main article: Sanofi Pasteur

In 2005, Sanofi Pasteur, vaccines division of Sanofi Group, was awarded a $97 Million United States Department of Health and Human Services (HHS) contract.[109]

BCG supply shortage 2012-

In 2011, a Sanofi Pasteur plant flooded, causing it problems with mold.[110] The facility, located in Toronto, Ontario, Canada, produced BCG vaccine products, made with the Glaxo 1077 strain,[111] such as a tuberculosis vaccine ImmuCYST, a BCG Immunotherapeutic -a bladder cancer drug. By April 2012, the FDA had found dozens of documented problems with sterility at the plant including mold, nesting birds and rusted electrical conduits.[110] The resulting closure of the plant for over two years resulting in shortages of bladder cancer and tuberculosis vaccines.[112] The Toronto Sanofi plant[113] On 29 October 2014 Health Canada gave the permission for Sanofi to resume production of BCG.[114]

COVID-19 Vaccine

Sanofi together with GSK signed a deal with US government's Operation Warp Speed to provide 100 million doses COVID-19 vaccine for up to 2.1 billion USD, if the vaccine is approved.[115]

As of August 2020, COVID-19 vaccine development in Sanofi underscores its fundamental competitiveness weakness, that management has been struggling and failed to deal with for past many years beyond cutting more cost. Unfortunately, even though Sanofi-GSK approach is based on pre-existing, approved platform and technology (as with Flublok flu) without reinventing the wheel of the necessary infrastructure[116], the company lags behind many other rivals in delivering a working vaccine. Sanofi plans to start Phase 1 clinical testing only in September and expects emergency use approval in first half 2021. [117] Competitors such as Novavax already completed Phase 1 with promising results [118] and Moderna-NIH already initiated its Phase 3 trial [119]. According to CNBC reports [120], as part of the 2.1 billion US government deal, more than 750 million goes to supporting Sanofi-GSK in vaccine development and clinical trials. Sanofi turns out "accelerate" the development via smaller biotech firm Translate Bio, with a 425 million partnership. [121]

Associations

Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA),[122] Biotechnology Industry Organization (BIO),[123] and Pharmaceutical Research and Manufacturers of America (PhRMA).[124]

Sanofi's vaccine subsidiary, Sanofi Pasteur, is a member of EuropaBio.[125]

Aventis Foundation

The Aventis Foundation, a German charitable trust, was established in 1996, as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education and healthcare research.

gollark: I kind of want a copy of this malware now.
gollark: Fun fact: The S in IoT stands for "security".
gollark: It really tells you something about their quality control.
gollark: If someone *is* installing malware, they might eventually install *functional* malware.
gollark: Did someone ping me?

See also

Notes
  1. Total reduced its stake to less than 5% in 2011.[102]

References
  1. "Annual Report 2018" (PDF). Retrieved 25 February 2017.
  2. "Form 20-F 2018". EDGAR. 8 March 2019. Retrieved 27 November 2019.
  3. Eric Palmer and Carly Helfand for FiercePharma. 4 March 2014 The top 10 pharma companies by 2013 revenue
  4. "Börse Frankfurt (Frankfurt Stock Exchange): Stock market quotes, charts and news". boerse-frankfurt.de. Archived from the original on 8 February 2019. Retrieved 23 May 2017.
  5. "Sanofi-Aventis to sign deal to build flu vaccine plant in China – source". Forbes. 23 November 2007. Retrieved 19 April 2009.
  6. "Le fondateur de Sanofi est mort". lexpress.fr. 28 December 2012. Retrieved 4 June 2015.
  7. CPE. Chemical & Process Engineering. L. Hill. 1964. p. 83.
  8. Sneader, Walter (13 September 1985). Drug discovery: the evolution of modern medicines. Wiley. ISBN 9780471904717.
  9. Staff, The Pharma Letter. Sept 20, 1993 Sanofi Extends Holding in Chinoin
  10. Chinoin listing in at securities.com Page accessed 5 February 2016
  11. Collins, Joseph C.; Gwilt, John R. (2000). "The Life Cycle of Sterling Drug, Inc" (PDF). Bull. Hist. Chem. 25 (1): 22–27.
  12. Sanofi-Synthélabo Form 20F for the Fiscal Year ended 31 December 2002
  13. Denis Cosnard for Les Echos. 11 December 1991. Synthélabo s'offre Delalande
  14. Denis Conard for Les Echos. 17 October 1991 Synthélabo rachète les laboratoires Delagrange
  15. Bibliothèque nationale de France Laboratoires Delagrange Page accessed 24 August 2016
  16. Tom Meek for PMLiVE 24 May 2013 A look back at Sanofi's merger with Synthélabo
  17. Aventis Form 20-F for the fiscal year ended 31 December 2002
  18. Arturo Bris and Christos Cabolis, Corporate Governance Convergence Through Cross-Border Mergers The Case of Aventis, Chapter 4 in Corporate Governance and Regulatory Impact on Mergers and Acquisitions: Research and Analysis on Activity Worldwide Since 1990. Eds Greg N. Gregoriou, Luc Renneboog. Academic Press, 26 July 2007
  19. Lawton Robert Burns The Business of Healthcare Innovation Cambridge University Press, 26 July 2012
  20. Meier, Barry (11 June 1996). "Blood, Money and AIDS: Haemophiliacs Are Split; Liability Cases Bogged Down in Disputes". The New York Times.
  21. Pollack, Andrew (24 June 2000). "Aventis Unit Sets Big Investment in Biotechnology Start-Up". The New York Times. Retrieved 27 November 2019.
  22. "Aventis to Sell Agriculture Unit". The New York Times. Bloomberg News. 16 November 2000. Retrieved 27 November 2019.
  23. CNN Money. 2 October 2001 Bayer buys CropScience
  24. Candace Hoffmann for First Word Pharma. 8 September 2003 Aventis inks deal with Regeneron for collaboration on cancer therapy
  25. Gever, John (19 November 2011). "FDA Approves Eylea for Macular Degeneration". MedpageToday.com. Retrieved 16 October 2013.
  26. Ciombor KK; et al. (2013). "Aflibercept". Clin Cancer Res. 19 (8): 1920–1925. doi:10.1158/1078-0432.CCR-12-2911. PMC 3710732. PMID 23444216.
  27. "2012 Notifications". U.S. Food and Drug Administration (FDA). 13 February 2018. Archived from the original on 26 December 2019. Retrieved 25 December 2019.
  28. Timmons, Heather (3 April 2004). "Aventis Invites Novartis To Counter Sanofi's Bid". The New York Times. Retrieved 27 November 2019.
  29. Timmons, Heather (27 April 2004). "France Helped Broker the Aventis-Sanofi Deal". The New York Times. Retrieved 27 November 2019.
  30. "Aventis Plan Is Rejected". The New York Times. Bloomberg News. 24 April 2004. Retrieved 27 November 2019.
  31. Kimberly S Cleaves and Ann M Thayer Warning, merge with care: Sanofi-Aventis Modern Drug Discovery, August 2004:21-26
  32. Zielbauer, Paul von (4 September 2006). "Iraqis Infected by H.I.V.-Tainted Blood Try New Tool: A Lawsuit". The New York Times. Retrieved 27 November 2019.
  33. BMS Press Release. 8 December 2006 Preliminary Injunction Against Apotex Upheld on Appeal
  34. Aaron Smith for CNNMoney.com 26 October 2006 Bristol CEO Dolan gets fired: Company says it heeded request of a federal monitor
  35. Donald Zuhn for Patent Docs. 9 November 2011 Sanofi-Aventis v. Apotex Inc. (Fed. Cir. 2011)
  36. Linda a. Johnson for Associated Press 8 February 2012 Apotex pays Bristol, Sanofi damages over Plavix Archived 5 March 2016 at the Wayback Machine
  37. Carolina Bolado for Law360 14 March 2013. Bristol-Myers Escapes $3.4B Apotex Suit Over Plavix Deal
  38. Winslow, Ron (10 November 2009). "Sanofi Expands Regeneron Deal". The Wall Street Journal. Retrieved 27 November 2019.
  39. Genetic Engineering and Biotechnology News. 11 November 2009 Sanofi-Aventis Commits Over $2.8B to Regeneron in mAb Discovery Alliance
  40. FierceBiotech. Sanofi-Aventis: A timeline of biopharma deals
  41. Andy Tisman for IMS Health 2010 The Rising Tide of OTC in Europe
  42. "Drug Maker Sanofi-Aventis Buys Chattem for $1.9 Billion". The New York Times. Reuters. 21 December 2009. Retrieved 27 November 2019.
  43. "Sanofi-Aventis to buy Czech generic drug maker". The New York Times. 22 September 2008. Retrieved 27 November 2019.
  44. Leigh Kamping-Carder for Law360. 20 May 2010 Brazil Clears Sanofi's $635M Medley Pharma Buy
  45. Gareth Macdonald for PharmaTechnologist, 15 April 2009 Sanofi beats Teva in Medley melee
  46. "Sanofi snaps up India's Shantha for $784M". FierceBiotech.
  47. Gryta, Thomas; Spencer, Mimosa (9 October 2010). "Sanofi Cuts Jobs, Counters Genzyme". The Wall Street Journal. Retrieved 27 November 2019.
  48. Phil Serafino for Bloomberg News. 28 October 2010 Sanofi-Aventis to Buy BMP Sunstone to Expand in China
  49. Mennella, Noelle (6 May 2011). "Sanofi changes name, pace of acquisitions to slow". Reuters. Retrieved 7 May 2011.
  50. Nicholson, Chris V. (16 February 2011). "Sanofi Agrees to Buy Genzyme for $20.1 Billion". The New York Times. Retrieved 27 November 2019.
  51. Arlene Weintraub for Xconomy. 10 January 2012 Warp Drive Bio Launches With $125M from Third Rock, Greylock, Sanofi
  52. Alnylam, TTR Amyloidosis (FAP)
  53. Bray, Chad (13 January 2014). "Sanofi Unit to Buy $700 Million Stake in Rare Disease Company". The New York Times. Retrieved 27 November 2019.
  54. Bloomberg News 24 March 2014
  55. French drugmaker Sanofi sacks CEO, shares drop, Natalie Huet and Noëlle Mennella, Reuters news agency, New York 29 October 2014. Retrieved: 6 July 2015.
  56. Sanofi : Sanofi Appoints Olivier Brandicourt as Chief Executive Officer, Sanofi corporate website, 19 February 2015. Retrieved: 6 July 2015.
  57. Silverman, Ed (24 February 2015). "French Government Slams Sanofi Over Brandicourt Pay Package". The Wall Street Journal. Retrieved 6 July 2015.
  58. Eric Palmer (26 June 2014). "Sanofi buys Dubai's Globalpharma to produce generics in the Middle East". Questex LLC. Retrieved 24 February 2017.
  59. "Genzyme to Buy Caprelsa from AstraZeneca for Up to $300M - GEN News Highlights - GEN". Genengnews.com. 27 July 2015.
  60. "Regeneron, Sanofi Launch $2B+ Immuno-Oncology Collaboration - GEN News Highlights - GEN". Genengnews.com. 28 July 2015.
  61. "UPDATED: Struggling Sanofi paying $1.8B to partner with Regeneron on immuno-oncology". FierceBiotech.com.
  62. "Aiming for top dog status, Sanofi and Boehringer swap animal and consumer health units". FiercePharma.com.
  63. "Sanofi – Sanofi to acquire Protein Sciences – Sanofi". mediaroom.sanofi.com.
  64. Hirschler, Ben (22 January 2018). "Biotech M&A takes off as Sanofi and Celgene spend $20 billion". Reuters.
  65. Blamont, Matthias (30 January 2018). "Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom". Reuters.
  66. "Sanofi: Press Releases, Monday, December 9, 2019".
  67. "Sanofi Pushes Further into Immuno-Oncology with $2.5 Billion Synthorx Takeover".
  68. https://uk.reuters.com/article/us-sanofi-regeneron/u-s-regeneron-to-buy-back-5-billion-stake-held-by-sanofi-idUKKBN2311TC
  69. https://uk.reuters.com/article/uk-sanofi-translate-bio/sanofi-clinches-2-billion-vaccines-deal-with-translate-bio-idUKKBN23U0LF
  70. "UK signs deal with GSK and Sanofi".
  71. "U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine". CNBC.
  72. "Annual Report 2005 on SEC Filing Form 20-F". Sanofi. 31 March 2006. Retrieved 22 February 2017.
  73. "Annual Report 2010 on SEC Filing Form 20-F". Sanofi. 1 March 2011. Retrieved 22 February 2017.
  74. "Annual Report 2015 on SEC Filing Form 20-F". Sanofi. 4 March 2016. Retrieved 22 February 2017.
  75. "Form 20-F 2016". EDGAR. 8 March 2019. Retrieved 27 November 2019.
  76. "Form 20-F 2017". EDGAR. 2 March 2018. Retrieved 27 November 2019.
  77. "Inline XBRL Viewer". www.sec.gov. Retrieved 3 June 2020.
  78. "FDA approves new multiple sclerosis treatment Aubagio" (Press release). U.S. Food and Drug Administration (FDA). 12 September 2012. Archived from the original on 13 September 2012. Retrieved 14 September 2012.
  79. "kaléo". kaléo.
  80. Thomas, Katie (1 February 2013). "Brothers Develop New Device to Halt Allergy Attacks". The New York Times. Retrieved 27 November 2019.
  81. "All Allerject epinephrine auto-injectors recalled". Cbc.ca.
  82. "Sanofi Canada Issues Voluntary Nationwide Recall of Allerject Due to Potential Inaccurate Dosage Delivery" (PDF). Allerject.ca. Retrieved 22 September 2018.
  83. "Auvi-Q® (epinephrine injection, USP)". Auvi-q.com.
  84. "UPDATED: Sanofi US Issues Voluntary Nationwide Recall of All Auvi-Q Due to Potential Inaccurate Dosage Delivery". U.S. Food and Drug Administration (FDA). 30 October 2015. Archived from the original on 3 February 2017. Retrieved 23 May 2017.
  85. "Sanofi Canada Issues Voluntary Nationwide Recall of Allerject® Due to Potential Inaccurate Dosage". Newswire.ca.
  86. "Welcome to EpiPen® 101". Epipen101.ca. 19 March 2015.
  87. Reprints, Cynthia Koons CynthiaLKoons Robert Langreth RobertLangreth. "How Marketing Turned the EpiPen Into a Billion-Dollar Business". Bloomberg.com.
  88. "Sanofi's Auvi-Q recall puts Mylan's rival EpiPen in full control of blockbuster market – FiercePharma". Fiercepharmamarketing.com.
  89. "It's open season for Mylan's EpiPen as Sanofi, Teva stumble – FiercePharma". Fiercepharma.com.
  90. Lisa M. Jarvis for Chemical and Engineering News. 14 January 2008 Isis, Genzyme In Heart Drug Deal
  91. "F.D.A. Approves Genetic Drug to Treat Rare Disease". The New York Times. 29 January 2013. Retrieved 27 November 2019.
  92. "Annual Review 2008" (PDF). Sanofi-Aventis. Retrieved 19 April 2009.
  93. "Mozobil approved for non-hodgkin's lymphoma and multiple myeloma" (Press release). Monthly Prescribing Reference. 18 December 2008. Retrieved 3 January 2009.
  94. "Mozobil approved for non-Hodgkin's lymphoma and multiple myeloma" (Press release). Monthly Prescribing Reference. 18 December 2008. Retrieved 3 January 2009.
  95. Kolata, Gina (9 July 2013). "Rare Mutation Ignites Race for Cholesterol Drug". The New York Times. Retrieved 27 November 2019.
  96. Alirocumab on Regeneron's website Archived 16 April 2012 at the Wayback Machine
  97. John Carroll for FierceBiotech 7 March 2014 UPDATED: Regeneron, Sanofi and Amgen shares suffer on FDA's frets about PCSK9 class
  98. John Carroll for FierceBiotech 22 November 2013 Regeneron, Sanofi hit a trio of goals in first PhIII test of rheumatoid arthritis drug
  99. PharmaLive. 4 September 2019 Sanofi picks CEO successor
  100. Sagonowsky, Eric. "Sanofi recruits veteran French auto executive to replace outgoing CFO Contamine". FiercePharma. Retrieved 4 July 2018.
  101. "Annual Report 2013" (PDF). Sanofi-Aventis. Archived from the original (PDF) on 26 March 2014. Retrieved 13 April 2014.
  102. MarketWatch 29 April 2011 Total CFO says firm cut Sanofi stake to under 5%
  103. "Sanofi-Aventis : regroupement à Paris." Le Journal du Net. Retrieved on 28 September 2010.
  104. Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
  105. "InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 2008-08-25.
  106. Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 15 October 2009. Retrieved 25 August 2008.
  107. Sanofi-aventis, Charite University Sign Cooperation Agreement News article from InfoGrok.
  108. "Sanofi Earns Slump in Q3 as Competition Heats Up". The New York Times. 25 October 2012.
  109. "Sanofi pasteur Awarded $97 Million HHS Contract to Accelerate Cell-Culture Pandemic Influenza Vaccine Development". 4 January 2005. Archived from the original on 25 April 2005. Retrieved 12 June 2013.
  110. "April 2012 Inspectional Observations (form 483)", U.S. Food and Drug Administration (FDA), Vaccines, Blood & Biologics, 12 April 2012, retrieved 29 January 2016
  111. Fine, P.E.M (2004). Issues relating to the use of BCG in immunization programmes: A discussion document, WHO/V&B/99.23 (PDF). Geneva: WHO. Archived from the original (PDF) on 21 October 2012.
  112. Palmer, Eric (10 September 2014), "Merck again shipping BCG cancer treatment but Sanofi still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma
  113. Palmer, Eric (12 July 2012), "Merck again shipping BCG cancer treatment but Sanofi still is not: Shortages of bladder cancer and tuberculosis treatment have persisted for two years", FiercePharma
  114. Palmer, Eric (31 March 2015), "Sanofi Canada vax plant again producing ImmuCyst bladder cancer drug", FiercePharma, retrieved 29 January 2016
  115. Sanofi and GSK selected for Operation Warp Speed to supply United States Government with 100 million doses of COVID-19 vaccine, 31 July 2020, retrieved 7 August 2020
  116. Sanofi and GSK land $2.1 billion deal with U.S. for Covid-19 vaccine development and 100 million doses, 31 July 2020, retrieved 7 August 2020
  117. Sanofi accelerates coronavirus vaccine plans, 24 June 2020, retrieved 7 August 2020
  118. Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate, 4 August 2020, retrieved 7 August 2020
  119. Phase 3 clinical trial of investigational vaccine for COVID-19 begins, 27 July 2020, retrieved 7 August 2020
  120. U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine, 31 July 2020, retrieved 7 August 2020
  121. Sanofi, a straggler in the Covid-19 vaccine race, accelerates its plans, 23 June 2020, retrieved 7 August 2020
  122. "The Pharmaceutical Industry in Figures – 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 16 September 2008. Retrieved 25 August 2008.
  123. "BIO Member Directory – BIO". BIO. Retrieved 22 September 2018.
  124. "Members – PhRMA". Phrma.org. Retrieved 22 September 2018.
  125. "Archived copy". Archived from the original on 27 April 2014. Retrieved 19 April 2014.CS1 maint: archived copy as title (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.